OmniAb Q1 2025 revenue $4.2M (+10% YoY), net loss $18.2M; lowers opex guidance

OmniAb, Inc.

2025-Q1 EPS reported -$0.17 revenue$4,154,000

Q1 revenue $4.2M (vs $3.8M in Q1 2024); net loss $18.2M ($0.17/share) vs $19.0M ($0.19/share) prior year.
Cash $43.6M at March 31, 2025; FY2025 revenue guidance reaffirmed $20-25M; opex guidance lowered to $85-90M from $90-95M.
Entered three new platform license agreements (Wyss, Takis, Orion); Orion deal includes $250K upfront and >$55M milestones.
Post-quarter asset sale to Angelini Pharma for Kv7.2 program: $3M upfront, >$170M milestones plus royalties.
Partner updates: Immunovant batoclimab positive MG/CIDP results; Teva Phase 2 celiac trial; Sugemalimab EMA submission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.